Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.35 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169017 | 0.89 | F2 (0.40) | F2CNR1CNR2GBA2GBA1 | |
| SCHEMBL29706450 | 0.75 | CYP1A2 (0.52) | F2AKR1B1CYP1A2CYP2A6 | |
| SCHEMBL5682912 | 0.75 | CYP1A2 (0.52) | F2AKR1B1CYP1A2CYP2A6 | |
| SCHEMBL13169570 | 0.73 | GBA2 (0.35) | CNR1CNR2GBA2GBA1ADRB2 | |
| SCHEMBL13169565 | 0.72 | GBA2 (0.35) | CNR1CNR2GBA2GBA1ADRB2 | |
| SCHEMBL13169566 | 0.72 | SLC5A2 (0.39) | CNR1CNR2GBA2GBA1ADRB2 | |
| SCHEMBL17919574 | 0.72 | CYP1A2 (0.48) | F2CYP1A2CYP2A6 | |
| SCHEMBL13168773 | 0.71 | PDE4A (0.42) | PARP1 | |
| SCHEMBL14949293 | 0.71 | F2 (0.46) | F2TACR1AKR1B1 | |
| SCHEMBL13169569 | 0.71 | SLC5A2 (0.36) | SLC5A2S1PR3CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | F2 1475/4885TACR1 75/4885CNR1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.